Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERTIS CV: Ertugliflozin CV Outcomes in T2DM
NCT01986881Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2013
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ertugliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoints: Major Adverse Cardiovascular Events at 6 years and Change from Baseline in Hemoglobin A1c at 18 weeks. Started Nov 2013; status: completed.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01986881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01986881.